Navigation Links
A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Date:11/16/2011

NEW YORK, Nov. 16, 2011 /PRNewswire/ -- Oligomerix, Inc. presented results at the Society for Neuroscience meeting in Washington D.C. which demonstrated that tau protein forms neurotoxic oligomers with a newly discovered enzymatic function. This proteolytic function results in tau's self-fragmentation and in the degradation of other proteins suggesting a mechanism for its neurotoxic mode-of-action. Furthermore, certain tau oligomer species that contained the highest level of activity also proved to be the most toxic to cultured neurons. Tau's enzymatic activity may play a key role in Alzheimer's disease (AD) progression and therefore may represent an important therapeutic intervention point.

James Moe, President and CEO of Oligomerix, Inc., stated, "Recent advances in the field indicate that tau oligomers are involved in Alzheimer's disease progression and inhibit memory formation.  Inhibiting the tau oligomer protease may be an effective intervention for not only improving cognitive function, but also for interrupting disease progression."

The Alzheimer's Association estimates that there are 5.4 million AD sufferers in the US alone that require 14.9 million unpaid caregivers and costs the US economy approximately $183 billion every year.  There are no FDA approved therapeutics that alter the course of disease or slow its progression. Tau protease pathology may represent a new target for slowing or arresting disease progression.

ABOUT OLIGOMERIX

Oligomerix, Inc. is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches, and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity.  The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.  The Company is seeking strategic partners to help accelerate its exciting tau protease program.

For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:
Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

Tiberend Strategic Advisors, Inc.
Andrew Mielach, Media
212-827-0020
amielach@tiberend.com


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scripps Research team discovers treatable mechanism responsible for often deadly response to flu
2. Oxidation mechanisms at gold nanoclusters unraveled
3. New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
4. Finding a protective mechanism for retinal cells could save sight
5. Scientists use math modeling to predict unknown biological mechanism of regulation
6. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
7. Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
8. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
9. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
10. DNA duplication: A mechanism for survival of the fittest
11. New Insights into the Mechanism of Action of Antipsychotic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... Rob Lowe ... public television series. This series, called "Informed," focuses on issues that are important to ... on the climate change issue, which has been a hot topic around the world ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... FireflySci, Inc ... Founded in late 2014, FireflySci had the goal of bringing their powerful cuvette ... continues to shape the path that FireflySci is going on as they add yet ...
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
Breaking Biology News(10 mins):